en-USen-GB
  • Tokyo 2-3 December 2019
    Tokyo 2-3 December 2019
  • Zurich 28-30 October 2019
    Zurich 28-30 October 2019
  • Peapack 14-16 October 2019
    Peapack 14-16 October 2019
  • Brussels 15-17 May 2019
    Brussels 15-17 May 2019
  • Danbury 8-10 April 2019
    Danbury 8-10 April 2019
  • Tokyo 5-6 November 2018
    Tokyo 5-6 November 2018
  • Paris, France 23-25 October 2018
    Paris, France 23-25 October 2018
  • Philadelphia, USA 2-4 October 2018
    Philadelphia, USA 2-4 October 2018
  • Princeton 1-3 May 2018
    Princeton 1-3 May 2018
  • Darmstadt, 15-17 May 2018
    Darmstadt, 15-17 May 2018

WHO WE ARE

The eClinical Forum is a global network of peers. It provides a non‐competitive environment for innovation, learning and collaboration in clinical research.


News from the eCF

Login to also view news for Members.

FDA and OHRP Issue Final Guidance on the Use of Electronic Informed Consent 12/15/2016

Re-Posted from eCF LinkedIn Group

  • 16 December 2016
  • Author: REG Team
  • Number of views: 12586
  • 0 Comments
FDA and OHRP Issue Final Guidance on the Use of Electronic Informed Consent 12/15/2016

The Food and Drug Administration (FDA) and Office for Human Research Protections (OHRP) published final guidance aimed at providing answers to commonly asked questions about using electronic systems and processes that may employ multiple electronic media to obtain informed consent for both HHS-regulated human subject research and FDA-regulated clinical investigations of medical products, including human drug and biological products, medical devices, and combinations thereof. This guidance finalizes the draft guidance entitled “Use of Electronic Informed Consent in Clinical Investigations--Questions and Answers” issued in March 2015. The final guidance was developed in collaboration with FDA and OHRP and is issued as a joint final guidance.

Final Guidance for Industry: “Use of Electronic Informed Consent--Questions and Answers.”
Federal Register Notice:
https://www.gpo.gov/fdsys/pkg/FR-2016-12-15/pdf/2016-30146.pdf
https://www.gpo.gov/fdsys/pkg/FR-2016-12-15/html/2016-30146.htm

Informed consent is the process of providing a subject with adequate information to allow for an informed decision about his or her voluntary participation in the clinical investigation. FDA believes that informed consent should include a process that facilitates the subject’s comprehension of the information and allows adequate opportunity to ask questions and consider whether or not to participate. Furthermore, this process often continues beyond obtaining the subject’s initial consent at the time of enrollment. It may involve providing information as the clinical investigation progresses or as the subject or situation requires.

Print
Tags:
Rate this article:
5.0

Theme picker

Not a member?
Visit the Membership page to learn 
How To Become a Member
(Join the eClinical Forum and learn how to leverage existing and emerging technologies for electronic clinical trials. Access an eClinical community, member-only knowledge, events and forums)

«January 2020»
MonTueWedThuFriSatSun
303112345
6789101112
13141516171819
20212223242526
272829303112
3456789